Real-World Treatment Patterns and Survival Among Adults With Stage IV Colorectal Cancer, 2018-2023: A SEER Population-Based Cohort Study
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Purpose. About one in five patients with colorectal cancer presents with metastatic disease, and many receive no recorded anticancer treatment. We described treatment patterns and examined survival differences by race/ethnicity, county income and rurality among adults with Stage IV colorectal cancer. Methods. Retrospective cohort of adults aged 20 years or older diagnosed in 2018-2023 in the Surveillance, Epidemiology, and End Results (SEER) program (n = 44,507 analyzed). Treatment was grouped as surgery plus chemotherapy, chemotherapy without surgery, surgery without chemotherapy, radiation only, or no recorded treatment. We used logistic regression, Kaplan-Meier methods and sequentially adjusted Cox models (3-month landmark analysis for treatment). Results. Overall, 24.8% had no recorded treatment (crude median survival 1 month). Age 75 or older versus under 50 carried the highest odds of no recorded treatment (odds ratio 7.26, 95% CI 6.56-8.03); odds were also higher for Black patients (1.31, 1.22-1.41). Three-year survival was 18.6% for Black versus 23.1% for White patients. Adjustment for treatment group attenuated the Black-White hazard ratio from 1.18 to 1.13; income and rurality estimates were unchanged. The Black-White difference was largest under age 50 (hazard ratio 1.45, 1.31-1.60) and absent at 75 and older (1.01, 0.95-1.08). Conclusions. About one in four adults with Stage IV colorectal cancer had no recorded treatment, mostly older patients. Survival differences by race/ethnicity, county income and rurality persisted after adjustment, with only slight attenuation of the Black-White difference after adjustment for recorded treatment.
Source: Research Square
Author: Olakunle Olorunkemi
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
OpenAlex ID: W7235053244
